 CureVac NASDAQ: CVAC shares are trading higher after the company announced the appointment of Dr. Malte Greune as COO and the transition of Dr. Florian von der Mülbe to lead accelerated development of the RNA printer. Dr. Greune joins the company from Sanofi-Aventis Deutschland, where he held multiple management positions. 